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Communicating the beneﬁts, harms and risks of medical interventions: In
journals; to patients and public‘‘The inability to understand statistical information is not
a mental deﬁciency of doctors or patients but is largely due to
the poor presentation of the information.’’11. Introduction
Communicating the beneﬁts, harms and risks of medical inter-
ventions by practitioners to patients in consultations is dependent
on there being clearly communicated information and data avail-
able in journals and systematic reviews. In turn, good quality infor-
mation in journals and reviews is dependent on data being
comprehensively and competently collected and reported in the
ﬁrst place.2,3 But it is also essential that practicing clinicians
know how to access information and that undergraduate students
are taught how to do so: ‘the search engine is now as essential as
the stethoscope’.4 Furthermore, we not only need public under-
standing of science, but also scientists’ understanding of the public
if we are to make progress in this area.5
If doctors and patients are to be able to make good decisions
together6 about any medical intervention, it is necessary that clear,
reliable, accurate information about beneﬁts, risks and harms is
available for them to draw on in formats that are readily compre-
hensible. Patients seek help in order to beneﬁt and ﬁnd relief
from what ails them; doctors want to help and are more inclined
to do something rather than nothing.7 But all help comes at a price.
Weighing up the beneﬁts and harms to assess the risk is easier said
than done – particularly as the natural tendency is to emphasise
beneﬁts at the expense of harms8 http://www.biomedcentral.
com/1741-7015/5/12,9 www.jameslindlibrary.org/pdf/testing-
treatments-preface-arabic-trans-pdf – and is particularly difﬁcult
when the quality of the data and information source is poor. It
follows that the ﬁrst absolute requirement is for journal reports
to be comprehensively accurate about both beneﬁts and harms. If
this is to be possible, it is clear that when research is undertaken,
provision must be made prospectively in protocols, and elsewhere,
for collection of data about harms, side effects, and adverse events.
Bolt-on or integrated qualitative studies,10 and close involvement of
patients11 in the whole research process from formulation of trial
hypothesis through to writing up and dissemination of results,
will assist in ensuring that harmful outcomes are not overlooked.1743-9191/$ – see front matter  2008 Surgical Associates Ltd. Published by Elsevier Lt
doi:10.1016/j.ijsu.2008.11.0052. Decision making
Discussion between doctor and patient when considering any
medical intervention – be it aspirin or major surgery – will inevi-
tably require consideration of possible beneﬁts, harms and deter-
mination of potential risks to that individual patient. Seldom will
it be a single possible intervention with no alternative: it will
more likely involve comparisons of more than one possible inter-
vention, or set of interventions, and may also involve the need to
consider a series of different (alternative) interventions over
a considerable period of time (involving consideration of both
immediate and long-term outcomes) – perhaps in comparison
with a less complex alternative. For example, a woman just diag-
nosed with breast cancer, where alternative methods of surgery,
radiotherapy and chemotherapy, each with their own element of
risk for particular categories and stages of breast cancer, and their
potential for different outcomes dependent upon the particular
individual proﬁle and preferences of the woman, could be
proposed. Need for radiotherapy and chemotherapy, or even
further surgery, e.g., axillary dissection, may be contingent upon
ﬁndings at surgery A tall order for both doctor and patient’s deci-
sion-making skills! This is eloquently described by Dr. Jane Keirdon,
a practicing haematologist, who, when diagnosed with breast
cancer, found there were huge decisions to be made. Her decision
not to take Herceptin was made after ‘‘the immense privilege’’ of
being able to discuss it with professional oncologist colleagues12
– and in spite of excessive public clamour for Herceptin resulting
from media hype at that time when NICE (National Institute of
Health and Clinical Excellence) ruled against it.
But the adequate and proper communication of beneﬁts, harms
and risks by a doctor to his patient not only presupposes his ability
and skill in being able to do this, but also that the beneﬁts, harms
and risks have been adequately, clearly and properly communi-
cated in journal reports and systematic review that provide the
evidence, and are readily available. He must also be clear in his
own mind in order to be able to discuss this impartially with his
patients.3. Deﬁnitions
Perhaps we should start with deﬁnitions of the three words in
question – beneﬁt, harm and risk – using those provided in the
background reading paper sent to the invitees at an Academy ofd. All rights reserved.
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from a related paper by the CONSORT group.14Benefits: the totality of possible positive consequences of an
intervention. These are the opposite of harms against which
they must be compared.
Harms: the totality of possible adverse consequences of an
intervention. These are the opposite of benefits against
which they must be compared.
Risk: the probability of harm taking place. It is not possible to
directly compare benefits and risks because one is an
outcome while the other is the probability of an outcome.4. The importance of semantics; exposure of the topic
Semantics are important.15 The words ‘harm’ and ‘risk’ are
often confused and used incorrectly, even by those who should
know better. Many people have made efforts to point this out,
and have attempted to correct it.16,17 The BMJ recognised this
problem and devoted a ‘‘long overdue theme issue’’18 to exploring
how to balance beneﬁts and harms in healthcare in July 2004.19 In
September 2003 they had devoted a theme issue to communi-
cating risks because readers had said they would like to do
better.20 The Academy of Medical Sciences convened an invited
workshop that took place in September 2008 to explore ways of
developing methods of communicating beneﬁts and harms of
medical interventions through journals. The CMR International
Institute for Regulatory Science convened a workshop to consider
‘Measuring Beneﬁt and Balancing Risk: Strategies for the beneﬁt–
risk assessment of new medicines in a risk–averse environment’:
it was held in Washington DC in June 2008. The CONSORT Group
(Consolidated Standards of Reporting Trials) (http://www.consort-
statement.org) has given close attention to terminology. The
EQUATOR Network (www.equator-network.org) is working to
achieve transparency in reporting health research.21 All these
efforts are to be commended and welcomed if we are to improve
how communication of beneﬁts, harms and risks of medical inter-
ventions is conveyed, not just within journals, but also to patients
in consultations. If clinicians are not provided with clear reports,
they will not be able to help their patients properly in the consul-
ting room.5. Assessing and communicating risks: (a) of treatments in
consultations; (b) of preventive interventions
Doctors, patients and members of the public require readily
available up-to-date reliable complete information about medical
interventions, presented in an accessible, understandable format
so that they can weigh up the beneﬁts and harms to make satisfac-
tory and satisfying decisions not only in consultations, but also
increasingly when considering options of preventative medicine;
when being invited for screening; and in opportunistic approaches
by medical practitioners. The ‘reversal of approach’ in these latter
categories is of particular importance and signiﬁcance, but is often
forgotten or overlooked. The recent replacement by the General
Medical Council (GMC) of its guidance ‘the ethical considerations
of seeking consent’22 by ‘patients and doctors making decisions
together’6 is signiﬁcant and raises serious questions about the
perceived onus of responsibility.(a) In consultations:
When patients seek beneﬁt from health professionals it is in the
hope being cured or alleviated from what ails them. Doctors are
adjured to ‘‘ﬁrst, do no harm’’. The temptation for both parties to
do something, as opposed to nothing, can be overwhelming: but
more (or something) is not necessarily better.24 All medical inter-
ventions carry potential for harm, or they may indeed inﬂict
harm in the hope of an ultimate good outcome: the ‘cut, burn
and poison’ of cancer treatment, for example. This example obvi-
ously involves a basic team of three, each with their own ancillary
specialists, but working as a team. Developing and evaluating
complex interventions (deﬁned as those that contain several inter-
acting components) is complicated – the Medical Research Council
guidance for the their evaluation has recently been revised and
updated25 www.mrc.ac.uk/complexinterventsionsguidance. In the
clinic, this brings its own difﬁculties of risk assessment and
communication, particularly for patients, in having to consider
the pros and cons of a possible series of interventions, from a series
of specialists, with one decision possibly contingent upon another
over a long period of time.
(b) In public health
In public health medicine it has been said, quite rightly, that it is
even more important for the doctor to be certain of possible
outcomes in this reversal of approach of health profession to
patient. Cochrane and Holland explained this principle in 1971:
‘‘If a patient asks a medical practitioner for help, the doctor does
the best possible. The doctor is not responsible for defects in
medical knowledge. If, however, the practitioner initiates
screening procedures the doctor is in a very different situation.
The doctor should, in our view, have conclusive evidence that
screening can alter the natural history of disease in a signiﬁcant
proportion of those screened.’’26
Berry substantiated this recently when he said that the pros and
cons of screening should be spelled out to women considering
mammographic screening: ‘‘these are the beneﬁts as we know
them – they are uncertain. These are the risks as we know them
– and these are more certain.’’27,28 The Cochrane and Holland prin-
ciple is currently being disregarded by promoters and advocates of
mammographic screening29: screening proponents are defending
a contrary approach.12,30 General disregard for the 1968 WHO Prin-
ciples and practice of screening for disease has proved to be a costly
exercise both economically and for the general public. With hind-
sight, three important shortcomings to these principles have been
identiﬁed:
 the harmful effects of screening are not emphasised
sufﬁciently
 the criteria should emphasise that there should be an effective
and acceptable treatment for the disease
 the decision to introduce a screening programme should be
based on good quality evidence.315.1. Who is to weigh all this in the balance to determine the risks for
patients and the general public?
Some people – but certainly not all (decisions are not necessarily
made on a rational basis32) – will require to know and take account
of the potential harms in order to weigh them up against the hoped
for beneﬁts to determine whether they think that, on balance, it is
a risk worth taking. It can seem very attractive to ‘ﬁnd out’ until
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tive interventions that can lead to considerable harms which may
well be greater than any potential for beneﬁt.28 Particular harm is
inﬂicted if it leads to the patient’s regret of subsequently ﬁnding
out that the beneﬁts were known to be uncertain, and the harms,
although much more certain, had been inadequately presented,12
or maybe had not been presented at all. Entwistle and colleagues
have proposed a reasonable new ‘middle road’ approach to
communicating about screening that is likely to appeal to many
people: ‘consider an offer’.33
Care and caution is needed to ensure that enabling under-
standing does not lead to manipulation. This will require that those
charged with the governance of risk in society will need to widen
their research in partnership with users, to examine social factors
that go beyond the cognitive to the behavioural, including the social
context in which meanings are shaped. This will require attitudinal
shifts in policy makers, patients, purchasers, and professionals,
with potential consequences that are far reaching for individuals,
health services, health economics, and society.32
6. Communication: ethics and ‘framing’
The way that information is presented affects the proportion of
risk-takers and risk-avoiders, and is an ethically signiﬁcant act.34,35
As Tversky summarises:
The psychological principles that govern the perception of
decision problems and the evaluation of probabilities and
outcomes produce predicable shifts of preference when the
same problem is framed in different ways. The dependence of
preferences on the formation of decision problems is a signiﬁ-
cant concern for the theory of rational choice.
Choices involving gains are often risk averse and choices
involving losses are often risk-taking. It follows that if the proposition
is incomplete, the person’s decision will be affected: this is particu-
larly important if there is a sequential or contingent decision to be
made which may be further complicated by value-laden compo-
nents. Worry can be manipulated by the labelling of outcomes:
e.g., ‘20% gain, 80% loss’; or ‘30% survival, 70% mortality’. It should
be borne in mind that representing information as natural frequen-
cies fosters greater insight than percentages or probabilities.36
6.1. How can we improve and develop methods of communicating
beneﬁts and harms of medical interventions?
The necessity of being able to communicate risk effectively has
occupied the minds of international experts in the ﬁeld for some
time and has been given room for wide consideration and improve-
ment through journals19,20 and institutions.13 Others, too, have
focussed their attention on this topic – for example, the Patient
Involvement Unit of the Royal College of Physicians began a project
in August 2004 on Explaining the risk [sic] and beneﬁts of treatment
optionswww.rcplondon.ac.uk/college/PIU/piu_risk.asp. In July 2008,
The Lancet Student considered potential beneﬁts and harms and
the risks of speciﬁc interventions in children www.thelancetstudent.
com/category/articles/medical-ethics.
As alreadymentioned, the BMJ devoted two special issues in2003
and2004 to provide a plethora of practical and reﬂective papers from
peoplewhohave immersed themselves in the topic andwere keen to
convey their ﬁndings. These covered a range of aspects: practical;
legal; educational; use of internet resources; use of risk-communica-
tion tools (words, numbers, pictures, graphs, etc.) – decision aids
(http://www.ohri.ca/DecisionAid); research; illustrative case histo-
ries; commentaries; and much more besides. In 2008, the journal,
Arthritis Research and Review published a brief review.37 They foundthat the literature about communicating risk to patients is limited.
They noted that people tend to underestimate common risk and
overestimate rare risk; they respond to risks primarily on the basis
of emotion rather than facts, seem to be risk averse when faced
withmedical interventions, andwant information on even the rarest
of adverse events. They concluded that ‘‘patients and professionals
want much information about risks of medical interventions but
we do not know how best to meet expectations. The impact of con-
textualised information remains to be tested.’’
The Academy of Medical Sciences consulted from a wide range
of individuals during their scoping exercise in order to prepare
a background paper for invited delegates to the workshop they
held in September 2008, convened to explore the communication
of beneﬁts and harms in medical journals. Forty-six delegates
from leading organisations and institutions; universities; journals;
regulatory authorities; industry; and including eight individuals
from the Academy of Medical Sciences itself attended this work-
shop. The programme offered presentation of viewpoints from
the publication world; from those involved in industry and in
regulation; from various research aspects (including the integra-
tion of randomised and observational evidence); and from
academic speakers holding chairs for the public understanding
of risk and of risk management. It was envisaged that the output
of this workshop would be a short report that will make recom-
mendations for reporting the beneﬁts and harms of medical inter-
ventions in journal articles, and/or would provide a roadmap to
show how such a system might be developed. We eagerly await
their report.
All these efforts indicate a need to ﬁnd better andmore effective
ways of communicating risk both in journals and to patients and
the public – and to policy makers.
7. Conclusion
Currently, risk communication has to be set in the context of
shared decision making. As Edwards conjectured in his BMJ edito-
rial of 2003,38 it may be necessary to accept that with increased
involvement of patients, risk communication may, therefore, have
to be based more on values than on evidence. He offers this
conclusion:
The new medical conversation thus integrates risk communi-
cation into the doctor–patient interaction while remaining loyal
to core consulting values. The information offered should be
simple, relevant, and responsive to the needs and values of
individual patients, not assuming what is most important. There
should be a two-way exchange of opinions and values, as well as
information, seeking to maximise trust and support. This may
need to be done over a series of consultations rather than being
one event. Truthfulness is fundamental – but will leave uncer-
tainties. Yet acknowledging these uncertainties, and accepting
patients’ decisions, may enhance the role of and respect for
professionals, not diminish it. In this way a balance may be
struck between a ‘‘high touch’’ and a ‘‘high tech’’ approach.’’
If this is the case, it is clear that there is much work to be done if
health practitioners in consulting rooms are to help patients and
the public come to a better understanding of risks so that they
may make better and more satisfying and satisfactory decisions
together. This two-way exchanges of opinions, values and informa-
tion needs to occur in an atmosphere of mutual trust and respect if
it is to bear fruit.Conﬂict of interest statement
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